Corneal thinning following bevacizumab intrastromal injection for the treatment of idiopathic lipid keratopathy

Kristie J Sun; Albert S Jun; Kelley Bohm; Daniel Daroszewski; Samir Jabbour

doi:10.1016/j.ajoc.2022.101618

Corneal thinning following bevacizumab intrastromal injection for the treatment of idiopathic lipid keratopathy

Am J Ophthalmol Case Rep. 2022 Jun 24:27:101618. doi: 10.1016/j.ajoc.2022.101618. eCollection 2022 Sep.

Authors

Kristie J Sun^{1

2}, Albert S Jun², Kelley Bohm², Daniel Daroszewski², Samir Jabbour^{2

3}

Affiliations

¹ Case Western Reserve University School of Medicine, 9501 Euclid Ave, Cleveland, OH, USA, 44106.
² The Johns Hopkins Wilmer Eye Institute, 1800 Orleans St, Baltimore, MD, USA, 21287.
³ Department of Ophthalmology, Centre hospitalier de l'Université de Montréal, 1051 Sanguinet st, Montreal, QC, Canada, H2X 3E4.

Abstract

Purpose: To describe the occurrence of corneal thinning in a patient following intrastromal injection of bevacizumab to treat lipid keratopathy.

Observations: A 36-year-old female presented with decreased vision in her right eye with central posterior corneal haze and underwent a treatment regimen including artificial tears, cyclosporine 0.05% drops, prednisolone 1% and oral Valacyclovir 1g with no improvement. Neovascularization was noted at 18 months follow up and treated with intrastromal bevacizumab injections at 24 months. The feeder vessel was attenuated at 3- and 6-months post-injection, but tomography indicated sustained thinning and flattening of the cornea at the injection site contributing to the development of irregular astigmatism.

Conclusions and importance: Corneal thinning is an uncommon potential side effect of intrastromal bevacizumab injection that may affect postoperative visual acuity.

Keywords: Bevacizumab injection; Corneal thinning.

Publication types

Case Reports